Results 151 to 160 of about 83,365 (272)

Synergistic associations of metformin and GLP‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Background Metformin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) may reduce the risk of adiposity‐related cancers in patients with type 2 diabetes (T2D). The potential synergistic effects of these treatments on cancer incidence remain unclear, considering their distinct biological mechanisms and their associated effects on body ...
Alex E. Henney, Megan Heague, David R. Riley, Theresa J. Hydes, Matthew Anson, Uazman Alam, Daniel J. Cuthbertson   +6 more
wiley   +1 more source

Cardiovascular biomarkers and preeclampsia: A narrative review

European Journal of Clinical Investigation, EarlyView.
Preeclampsia (PE) is a complex pregnancy disorder linked to cardiovascular disease (CVD) through shared risk factors and epidemiological associations. Cardiovascular biomarkers are valuable for predicting, diagnosing and assessing PE, as well as estimating future CVD risk. This review explores current cardiovascular biomarkers used in clinical practice
Johana Ullmo, Madalina Nicoleta Nan, Mónica Cruz‐Lemini, Carmen Garrido‐Gimenez, Judit Platero, Álvaro García‐Osuna, Pablo García‐Manau, Marcel Twickler, Elisa Llurba   +8 more
wiley   +1 more source

Overcoming BET‐inhibitor JQ1 resistance in aggressive non‐small cell lung cancer by inducing ferroptosis via inhibition of the BRD2–FTH1 axis

The FEBS Journal, EarlyView.
Recent studies emphasize alternative functions of FTH1 relevant for nuclear processes, such as transcriptional regulation. This study shows a novel FTH1/BRD2 association in non‐small cell lung carcinoma (NSCLC). This nuclear interaction affects BRD2 protein stability in aggressive NSCLC cells.
Stefania Scicchitano, Cinzia Garofalo, Beatrice Stella, Gianluca Santamaria, Flora Cozzolino, Vittoria Monaco, Flavia Biamonte, Maria Monti, Eleonora Vecchio, Maria Concetta Faniello   +9 more
wiley   +1 more source

In vivo modeling of lethal congenital contracture syndrome 1 suggests pathomechanisms in cellular stress responses

The FEBS Journal, EarlyView.
Gle1 knockout mice fail to segregate cell lineages at the blastocyst stage, resulting in very early embryonic lethality. Gle1 knock‐in (KI) mice harboring a pathogenic variant giving rise to lethal congenital contracture syndrome 1 show both known and novel innervation defects, supportive of multiorgan pathology in human fetuses.
Tomáš Zárybnický, Sonja Lindfors, Saana Metso, Julia Koivula, Zoltan Szabo, Rasmus Valtonen, Mikko Tulppo, Johanna Magga, Samu Saarimäki, Sonja Bläuer, Ilkka Miinalainen, Risto Kerkelä, Petteri. T. Piepponen, Vootele Voikar, Juho Väänänen, Riikka Kivelä, Bhagwan Yadav, Hanna Lindgren, Pirkko Mattila, Fu‐Ping Zhang, Petra Sipilä, Reetta Hinttala, Satu Kuure   +22 more
wiley   +1 more source

Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma

Hepatology Research, EarlyView.
ABSTRACT Background Atezolizumab plus bevacizumab (AB) is a standard first‐line therapy for unresectable hepatocellular carcinoma (HCC). However, data on the efficacy and safety of AB rechallenge (re‐AB) after discontinuation are limited. Methods We conducted a retrospective analysis of 13 patients with unresectable HCC who received initial AB ...
Yuichiro Suzuki, Teiji Kuzuya, Leona Osawa, Yasuyuki Komiyama, Hitomi Takada, Shuya Matsuda, Masaru Muraoka, Mitsuaki Sato, Shinya Maekawa, Nobuyuki Enomoto, Hisanori Muto, Yoshihiko Tachi, Yoshiki Hirooka, Atsunori Tsuchiya   +13 more
wiley   +1 more source

Impact of Surgical Resection on Hepatocellular Carcinoma Following Systemic Drug Therapy: A Multicenter Retrospective Observational Study

Hepatology Research, EarlyView.
ABSTRACT Aim This study is aimed to evaluate the safety and outcomes of surgical resection in patients with hepatocellular carcinoma (HCC) treated with systemic therapy, address the therapeutic benefit, and identify candidates for surgery after systemic treatment.
Takamichi Ishii, Junichi Shindoh, Ikuo Nakamura, Seiko Hirono, Masaki Wakasugi, Akihiko Ichida, Takashi Hamada, Hajime Matsushima, Takahiro Nishio, Yukio Tokumitsu, Hidenori Takahashi, Yuji Morine, Shinichiro Yamada, Akiyoshi Nakakura, Susumu Eguchi, Kiyoshi Hasegawa, Etsuro Hatano   +16 more
wiley   +1 more source

Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT)

European journal of internal medicine, 2021
J. Varona, Millán García-Isidro, M. Moeinvaziri, M. Ramos-López, M. Fernández-Domínguez   +4 more
semanticscholar   +1 more source

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source

Primary Adrenal Insufficiency After COVID-19 Infection

AACE Clinical Case Reports, 2021
Julie R Sanchez, Melissa J. Cohen, Joseph L. Zapater, Yuval Eisenberg   +3 more
semanticscholar   +1 more source

Diagnostic Performance of Prothrombin Time and Activated Partial Thromboplastin Time in Children: A Service Evaluation

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Background Coagulation screening, consisting of prothrombin time (PT) and activated partial prothrombin time (aPTT), is routinely performed in paediatrics to identify bleeding disorders or guide peri‐procedural management. We evaluated the trends in utilisation and diagnostic yield of PT and aPTT testing as part of coagulation screening in a ...
Gerard Gurumurthy, Mikias Lemma, Lianna Reynolds, John Grainger, Jecko Thachil   +4 more
wiley   +1 more source